Specialty programme · No. 05

Our specialty: ketamine therapy.

Kenya's first low-dose ketamine programme for psychiatric conditions, since 2019. Monitored, hospital-grade, and reserved for adults whose severe or treatment-resistant condition has not responded to standard care.

Not a first-line treatment. Suitability is decided after assessment.

The BPL Acura-S syringe infusion pump used in the Parklands Mindcare Centre ketamine programme, set up for a monitored low-dose session
Dr. Alphonce Nabiswa attending a patient during a ketamine infusion at Parklands Mindcare Centre, with the critical care monitor displaying vital signs in the background
Treatment room · Suite 110 The patient's identity has been masked for privacy.

Where it sits in our practice

Most patients at Parklands Mindcare Centre are treated effectively with standard psychiatric care: assessment, medication, lifestyle support, and therapy referral where indicated (see services).

The ketamine programme is the specialty layer on top of that, reserved for the smaller group of patients with severe and treatment-resistant conditions where the literature, and Dr. Nabiswa's clinical experience, support a meaningful response. It is not a first-line treatment, and we do not offer it to every patient who asks for it.

In one paragraph

Ketamine acts on a different system in the brain than traditional antidepressants. At the low, monitored doses used in clinical psychiatric practice, it can produce a meaningful shift within hours and supports new neural connections that allow therapy and lifestyle change to take hold.

Mechanism

How ketamine works in the brain.

Ketamine acts by inhibiting N-methyl-D-aspartate (NMDA) receptors, which are involved in pain transmission and mood regulation. Blocking these receptors triggers a cascade of helpful changes:

  • A surge in glutamate, an excitatory neurotransmitter that supports learning, memory, and mood.
  • Downstream increases in serotonin and dopamine, two neurotransmitters closely tied to well-being.
  • A rise in brain-derived neurotrophic factor (BDNF), a protein that supports the growth and survival of neurons.

Together, these changes drive neuroplasticity: the brain forms new synaptic connections and strengthens existing ones. This is the mechanism behind ketamine's rapid antidepressant and anxiolytic effects. Ketamine also has anti-inflammatory properties, which appear to contribute to its benefits in chronic pain syndromes such as migraine and fibromyalgia.

Comparison

Why ketamine is different from standard antidepressants.

AspectStandard antidepressantsKetamine therapy
Time to effect3 to 6 weeksHours to days
Response rateAround 40 to 50%Around 70 to 80% in severe cases
MechanismSerotonin or norepinephrine reuptakeNMDA receptor modulation, glutamate, BDNF, neuroplasticity
Anti-suicidal effectSlow, indirectRapid, observed within hours in clinical practice

A note on suitability

Most patients do not need ketamine.

The vast majority of people who come to Parklands Mindcare Centre do well on standard psychiatric care: a thorough assessment, the right medication at the right dose, sleep and lifestyle support, and therapy where indicated. The specialty ketamine programme is reserved for severe and treatment-resistant cases. If ketamine is the right next step, we will say so, and explain why. If it is not, we will say that too.

Who it is for

Conditions we consider.

The programme is designed for adults with severe or treatment-resistant presentations across a defined set of neuropsychiatric conditions. Suitability is decided after a thorough psychiatric and medical assessment.

  • Treatment-resistant depression (after at least two adequate antidepressant trials)
  • Severe major depressive disorder, especially with significant suicidal ideation
  • Bipolar depression, alongside the underlying mood-stabilising regimen
  • Severe anxiety, panic disorder, and social anxiety that has not responded to standard care
  • Post-traumatic stress disorder, often as an adjunct to trauma-focused therapy
  • Severe, treatment-resistant obsessive-compulsive disorder
  • Acute suicidal ideation in the context of severe depression
  • Selected chronic pain syndromes, including migraine and fibromyalgia

Read the full conditions list

Honest framing

Is ketamine a cure?

No. Ketamine is not a cure, and we will never tell you that it is. What it can do, when administered correctly to the right candidate, is provide rapid and meaningful relief that creates a window for therapy, lifestyle change, and continued psychiatric care to take hold.

Critical information

  • Ketamine is not a cure.
  • Suitability is decided after a thorough assessment.
  • We do not offer ketamine to every patient who asks for it.
  • Ketamine is one of several treatments at Parklands Mindcare Centre, not the practice itself.

Read about our safety and monitoring.

Hospital-grade monitoring standards, vital sign tracking, and the clinical guarantees that govern every session of the ketamine programme.

See our safety standards